$116.61+9.13 (+8.49%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Rhythm Pharmaceuticals (RYTM) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
4 figures withheld by our checks. Each blank figure names its reason.
Business engineGrowing fast: revenue compounds ~178.5%/yr (FY21→FY25), net margin −103.6%. Worth your attention in FY25: Share count (+31.0%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲45.8%
189.8
FY21→FY25CAGR +178.5%/yr
Net income ($M)▲24.6%
−196.5
FY21→FY25CAGR —
Free cash flow ($M)▼2.4%
−116.6
FY21→FY25CAGR —
Diluted EPS▲28.3%
−3.11
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+31.0%
49.6mn → 65.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-104¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 81.0% → 89.7%. Net margin -103.6% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 280,748.0 | 189,757.0 | 130,126.0 | 77,428.0 | 23,638.0 | 3,154.0 | ▲45.8% | +178.5% |
Cost of revenue | 33,056.0 | 19,492.0 | 13,368.0 | 9,302.0 | 2,133.0 | 599.0 | ▲45.8% | +138.8% |
Gross profit | 247,692.0 | 170,265.0 | 116,758.0 | 68,126.0 | 21,505.0 | 2,555.0 | ▲45.8% | +185.7% |
Research & development | 179,665.0 | 167,340.0 | 237,957.0 | 134,951.0 | 108,630.0 | 104,128.0 | ▼29.7% | +12.6% |
Selling, general & admin | 255,273.0 | 194,941.0 | 144,304.0 | 117,532.0 | 92,032.0 | 68,486.0 | ▲35.1% | +29.9% |
Total operating expenses | 434,938.0 | 362,281.0 | 382,261.0 | 252,483.0 | 200,662.0 | 172,614.0 | ▼5.2% | +20.4% |
Operating incomefeeds ROC rank | −187,246.0 | −192,016.0 | −265,503.0 | −184,357.0 | −179,157.0 | −170,059.0 | ▲27.7% | — |
Other income, net | −4,997.0 | −4,026.0 | 5,247.0 | 243.0 | −1,962.0 | 100,447.0 | — | — |
Pretax income | −192,243.0 | −196,042.0 | −260,256.0 | −184,114.0 | −181,119.0 | −69,612.0 | ▲24.7% | — |
Income tax | 1,568.0 | 497.0 | 346.0 | 564.0 | 0.0 | 0.0 | ▲43.6% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −193,811.0 | −196,539.0 | −260,602.0 | −184,678.0 | −181,119.0 | −69,612.0 | ▲24.6% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −2.90 | −3.11 | −4.34 | −3.20 | 0.00 | −1.40 | ▲28.3% | — |
Diluted shares (mn) | 69.05 | 64.98 | 61.00 | 57.67 | 0.00 | 49.60 | ▲6.5% | +7.0% |
| Margins | ||||||||
Gross margin83rd pct in Healthcare | 88.2% | 89.7% | 89.7% | 88.0% | 91.0% | 81.0% | ▲0.0pp | +8.7pp |
Operating margin | −66.7% | −101.2% | −204.0% | −238.1% | −757.9% | −5391.9% | ▲102.8pp | +5290.7pp |
Net margin11th pct in Healthcare | −69.0% | −103.6% | −200.3% | −238.5% | −766.2% | −2207.1% | ▲96.7pp | +2103.5pp |
† TTM = trailing four quarters through 2026-09-30.
5 more years of statements and CSV export are on Premium, and 6 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Rhythm Pharmaceuticals' revenue last fiscal year?
Rhythm Pharmaceuticals reported revenue of $189.8M in fiscal 2025, up 45.8% from fiscal 2024.
What was Rhythm Pharmaceuticals' net income?
Rhythm Pharmaceuticals reported net income of −$196.5M in fiscal 2025, a net margin of −103.6%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

